

The original disclosure in Japanese was released on Nov. 9, 2021 at 16:00 (GMT+9)

Consolidated Financial Statements for the Second Quarter Ended September 30, 2021 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]

Company name: Takara Holdings Inc.
 Stock exchange listings: Tokyo Stock Exchange (1st section)
 Code number: 2531
 URL: <https://www.takara.co.jp/>
 Company representative: Mutsumi Kimura, President
 Contact: Masakazu Usami, General Manager of Financial & Investor Relations Dept.
 TEL : (075)241-5124

Quarterly statement filing date (as planned): November 12, 2021

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the six months ended September 30, 2021 (April 1, 2021 - September 30, 2021)

(1) Consolidated Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ended September 30, 2021		Six months ended September 30, 2020	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	141,213	-	127,784	(7.1)
Operating income (loss)	21,616	273.8	5,782	(24.1)
Ordinary income (loss)	21,884	268.4	5,940	(24.5)
Net income (loss) attributable to owners of the parent	10,050	263.9	2,761	(36.9)
Net income (loss) per share (Yen)	50.84		13.97	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	21,056	765.4	2,433	(12.3)

Since the "Accounting Standard for Revenue Recognition" (Corporate Accounting Standard No. 29), etc. has been adopted from FY2022, the above results is the amount after applying the accounting standard. Therefore, the rate of increase and decrease concerning sales compared to the previous year and is not stated.

(2) Consolidated Financial position

	As of September 30, 2021	As of March 31, 2021
	(Millions of yen)	(Millions of yen)
Total assets	328,097	306,918
Net assets	205,795	191,535
Equity ratio (%)	50.7	51.1
(Reference) Equity	166,385	156,884

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2021	Year ending March 31, 2022	Year ending March 31, 2022 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	21.00		29.00
Annual	21.00		29.00

Note: Correction of dividend forecast from the most recent dividend forecast : Yes

3. Forecast for the year ending March 31, 2022 (April 1, 2021 - March 31, 2022)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2022	
	(Millions of yen)	(%)
Net sales	289,000	-
Operating income (loss)	33,400	54.7
Ordinary income (loss)	33,800	54.1
Net income (loss) attributable to owners of the parent	16,100	52.3
Net income per share (Yen)	81.43	

Note: Correction of financial forecast from the most recent financial forecast : Yes

Since the "Accounting Standard for Revenue Recognition" (Corporate Accounting Standard No. 29), etc. has been adopted from FY2022, the above results is the amount after applying the accounting standard. Therefore, the rate of increase and decrease concerning sales compared to the previous year and is not stated.

4. Others

(1) Material changes in subsidiaries during this period

(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

(2) Accounting procedures specific to quarterly consolidated financial statements: No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard: Yes

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at the end of each period (Treasury stocks are included):

As of September 30, 2021 199,699,743 shares

As of March 31, 2021 199,699,743 shares

2) Number of treasury stocks at the end of each period:

As of September 30, 2021 1,995,490 shares

As of March 31, 2021 1,995,468 shares

3) Average number of outstanding shares in each period:

Six months ended September 30, 2021 197,704,258 shares

Six months ended September 30, 2020 197,704,590 shares

Contents of the attached document

1. Qualitative Information for the Six Months Ended September 30, 2021.....	2
(1) Consolidated Financial Results	2
(2) Consolidated Financial Position	4
(3) Qualitative Information Regarding Consolidated Forecasts.....	5
2. Consolidated Quarterly Financial Statements and Primary Notes.....	6
(1) Consolidated Balance Sheets.....	6
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income.....	8
(Consolidated Statements of Income)	8
(For the Six Months Ended September 30, 2021 and 2020)	
(Consolidated Statements of Comprehensive Income)	9
(For the Six Months Ended September 30, 2021 and 2020)	
(3) Consolidated Statements of Cash Flows.....	10
(4) Notes to Consolidated Financial Statements.....	11
(Notes on Premise of Going Concern)	11
(Notes on Material Changes in Shareholders' Equity)	11
(Changes in Accounting Policies)	11
(Segment Information)	12
(Revenue Recognition)	13
(Significant Subsequent Events)	14
○ Supplement for the Consolidated Quarterly Financial Statements	

1. Qualitative Information for the Six Months Ended September 30, 2021

The Accounting Standard for Revenue Recognition, etc. have been adopted from the beginning of the three months ended June 30, 2021. As a result, net sales in the six months ended September 30, 2021 have been recorded in accordance with the standard which is different from the standard applied to net sales in the six months ended September 30, 2020. Therefore, concerning explanation on net sales, gross profit, and SG&A expenses on a consolidated basis and of the Takara Shuzo segment, which were significantly impacted by the change in the standard, the rate of increase and decrease compared to the same period of the previous fiscal year is not stated. There was no impact on income items from operating income onwards. The effect of the application of the Accounting Standard for Revenue Recognition, etc. is described in “2. Consolidated Quarterly Financial Statements and Primary Notes (4) Notes to Consolidated Financial Statements (Changes in Accounting Policies).”

(1) Consolidated Financial Results

In the six months ended September 30, 2021, driven by the favorable performance of the Takara Shuzo International Group and the Takara Bio Group, net sales were ¥141,213 million, gross profit was ¥54,340 million, and SG&A expenses were ¥32,724 million. Operating income grew 273.8% year on year to ¥21,616 million, while ordinary income rose 268.4% year on year to ¥21,884 million, increasing both sales and income, absorbing the impact of the Accounting Standard for Revenue Recognition, etc. In addition, net income attributable to owners of the parent increased 263.9% year on year to ¥10,050 million, although loss on voluntary product recall of ¥1,567 million was posted under extraordinary loss.

Results by business segment were as follows.

[Takara Shuzo]

In the six months ended September 30, 2021, even in a comparison excluding the effect of application of the Accounting Standard for Revenue Recognition, etc., sales of raw alcohol, etc. and sake decreased. In addition, sales of light-alcohol refreshers decreased due to the voluntary product recall.

As a result, net sales for Takara Shuzo were ¥57,633 million, including the effect of the application of the Accounting Standard for Revenue Recognition, etc. of ¥(13,915) million. Cost of sales was ¥43,341 million, and gross profit was ¥14,291 million. SG&A expenses were ¥12,020 million due to efforts for cost reduction in addition to the effect of the application of the Accounting Standard for Revenue Recognition, etc. of ¥(13,915) million. Operating income was up 39.6% year on year to ¥2,270 million.

[Takara Shuzo International Group]

In the six months ended September 30, 2021, net sales of the Overseas Alcoholic Beverages Business increased 53.1% year on year to ¥7,005 million, mainly due to continued growth in sales of whiskey in the U.K. and the U.S. as well as an increase in sales of sake which had decreased in the previous fiscal year, affected by the coronavirus crisis. Net sales of the Japanese Food Wholesale Business in overseas markets increased 49.1% year on year to ¥40,410 million, primarily due to the ongoing recovery in the eating and drinking establishment market from the coronavirus crisis.

As a result, net sales for the Takara Shuzo International Group increased 49.4% year on year to ¥46,734 million. Cost of sales increased 43.4% year on year to ¥31,747 million. Consequently, gross profit increased 63.9% year on year to ¥14,987 million. SG&A expenses rose 12.0% year on year to ¥10,682 million, primarily due to an increase in personnel expenses and transportation costs, and operating income amounted to ¥4,304 million, compared to operating loss of ¥396 million in the six months ended September 30, 2020.

[Takara Bio Group]

In the six months ended September 30, 2021, although sales of gene therapy decreased year on year, sales of reagents, instruments, and CDMO increased year on year. In sales of reagents in particular, in addition to PCR testing-related products for the new coronavirus, sales of general research reagents, which are continuing to recover, increased.

As a result, net sales for the Takara Bio Group increased 81.4% year on year to ¥31,551 million. Cost of sales increased 44.7% year on year to ¥8,056 million in line with the improvement in the cost of sales ratio for CDMO. Consequently, gross profit increased 98.6% year on year to ¥23,495 million. SG&A expenses were up 16.1% year on year to ¥9,389 million, primarily due to an increase in personnel expenses and R&D expenses. Operating income increased 277.5% year on year to ¥14,105 million.

[Other]

In the six months ended September 30, 2021, net sales of the Other segment increased 3.1% year on year to ¥14,624 million. Cost of sales increased 2.4% year on year to ¥12,684 million. Consequently, gross profit increased 7.9% year on year to ¥1,940 million. SG&A expenses fell 4.1% year on year to ¥910 million, primarily due to a decline in personnel expenses, and

operating income was up 21.4% year on year to ¥1,029 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2020, to September 30, 2020)	Period under Review (from April 1, 2021, to September 30, 2021)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	24,284	19,315	(20.5)
Sake	6,792	4,718	(30.5)
Light-alcohol refreshers	24,024	18,808	(21.7)
Other alcoholic beverages	2,684	2,529	(5.8)
<i>Hon Mirin</i>	6,288	4,258	(32.3)
Other seasonings	4,976	4,079	(18.0)
Raw alcohol, etc.	5,114	3,922	(23.3)
Total	74,164	57,633	(22.3)
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	4,574	7,005	53.1
Japanese Food Wholesales Business in overseas markets	27,099	40,410	49.1
Other	35	29	(16.9)
Elimination of intra-Group transaction on consolidation	(424)	(710)	—
Total	31,286	46,734	49.4
Takara Bio Group			
Reagents	13,336	25,966	94.7
Instruments	466	712	52.6
CDMO	3,373	4,732	40.3
Gene therapy	215	140	(35.0)
Total	17,393	31,551	81.4
Reported segment total	122,844	135,919	10.6
Other	14,186	14,624	3.1
Segment total	137,030	150,544	9.9
Sales not allocated to business segments and intersegment transactions	(9,246)	(9,331)	—
Total	127,784	141,213	10.5

Notes: 1. Amounts include alcohol tax.

2. From the three months ended June 30, 2021, the names of the product categories of Takara Bio Group have been changed from “Research reagents,” “Scientific instruments” and “Contract services” to “Reagents,” “Instruments” and “CDMO.”

(Reference) [Before applying the Accounting Standard for Revenue Recognition]**Breakdown of sales results by product category**

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2020, to September 30, 2020)	Period under Review (from April 1, 2021, to September 30, 2021)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	24,284	24,173	(0.5)
Sake	6,792	6,066	(10.7)
Light-alcohol refreshers	24,024	23,115	(3.8)
Other alcoholic beverages	2,684	2,828	5.4
<i>Hon Mirin</i>	6,288	6,344	0.9
Other seasonings	4,976	5,093	2.4
Raw alcohol, etc.	5,114	3,928	(23.2)
Total	74,164	71,549	(3.5)
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	4,574	7,019	53.4
Japanese Food Wholesales Business in overseas markets	27,099	40,410	49.1
Other	35	29	(16.9)
Elimination of intra-Group transaction on consolidation	(424)	(710)	—
Total	31,286	46,748	49.4
Takara Bio Group			
Reagents	13,336	25,966	94.7
Instruments	466	712	52.6
CDMO	3,373	4,732	40.3
Gene therapy	215	140	(35.0)
Total	17,393	31,551	81.4
Reported segment total	122,844	149,849	22.0
Other	14,186	14,624	3.1
Segment total	137,030	164,474	20.0
Sales not allocated to business segments and intersegment transactions	(9,246)	(9,331)	—
Total	127,784	155,143	21.4

Note: For convenience of comparison, net sales for the six months ended September 30, 2021 are the amounts to which the Accounting Standard for Revenue Recognition, etc. are not applied.

(2) Consolidated Financial Position

As of September 30, 2021, current assets were ¥197,879 million, an increase of ¥14,771 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in cash and deposits of ¥5,012 million, an increase in inventories of ¥4,147 million, and an increase in notes and accounts receivable-trade of ¥3,744 million. Noncurrent assets were ¥130,218 million, an increase of ¥6,408 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥5,487 million in property, plant and equipment resulting from interior finishing work of Takara Bio USA, Inc.'s new office buildings, Takara Bio Inc.'s acquisition of manufacturing facilities, etc.

As a result, total assets were ¥328,097 million, an increase of ¥21,179 million compared with that at the end of the previous fiscal year.

As of September 30, 2021, current liabilities were ¥73,636 million, an increase of ¥17,367 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥8,890 million in other under current liabilities as a result of the recording of refund liabilities of ¥5,690 million following the application of the Accounting Standard of Revenue

Recognition, etc., as well as due to an increase in current portion of bonds of ¥10,000 million. Noncurrent liabilities were ¥48,665 million, a decrease of ¥10,447 million compared with that at the end of the previous fiscal year, primarily due to the transfer of bonds to current liabilities.

As a result, total liabilities were ¥122,302 million, an increase of ¥6,919 million compared with that at the end of the previous fiscal year.

As of September 30, 2021, total net assets were ¥205,795 million, an increase of ¥14,260 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in foreign currency translation adjustment of ¥4,974 million reflecting a weak yen, and due to an increase in noncontrolling interests of ¥4,759 million resulting from strong performance of the Takara Bio Group.

As a result, the equity ratio totaled 50.7%, compared with 51.1% at the end of the previous fiscal year.

In the six months ended September 30, 2021, net cash provided by operating activities increased ¥5,716 million year on year to ¥11,798 million primarily due to income before income taxes of ¥20,400 million, depreciation and amortization of ¥4,061 million, an increase in notes and accounts receivable-trade of ¥2,850 million, an increase in inventories of ¥2,472 million, and ¥6,365 million in income taxes paid.

Net cash used in investing activities resulted in expenditure of ¥12,066 million, an increase in expenditure of ¥8,963 million compared to the same period of the previous fiscal year primarily due to payments into time deposits of ¥10,757 million, proceeds from withdrawal of time deposits of ¥2,119 million, purchase of property, plant and equipment and intangible assets of ¥6,827 million, and subsidies received of ¥3,349 million.

Net cash used in financing activities resulted in expenditure of ¥5,620 million, compared with net cash provided by financing activities of ¥1,202 million in the same period of the previous fiscal year primarily due to cash dividends paid of ¥4,144 million.

As a result, cash and cash equivalents as of September 30, 2021, including effect of exchange rate change on cash and cash equivalents, stood at ¥58,775 million, down ¥4,085 million from the previous fiscal year-end.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the full-year consolidated results forecasts published on August 3, 2021 in consideration of recent performance trends.

For the fiscal year ending March 31, 2022, overall consolidated net sales are expected to exceed the previous forecast (announced on August 3, 2021) and reach a record high, with higher net sales for the Takara Shuzo International Group and the Takara Bio Group, although net sales for Takara Shuzo are projected to be lower than the forecast.

In terms of profit, operating income, ordinary income, and net income attributable to owners of the parent are expected to exceed the previous forecast and are projected to be an all-time high, with higher gross profit due to the increase in net sales and a decrease in the cost of sales ratio, despite an increase in SG&A expenses.

For further details of the revision to the consolidated business result forecast, please refer to “Revision of Consolidated Business Results Forecast and Dividend Forecast (Dividend Increase) for the Fiscal Year Ending March 31, 2022,” announced today (November 9, 2021). Also, for the details of forecasts for each business segment, please refer to pages 14/22-17/22 in “Supplement for the Consolidated Financial Statements.”

(Full-Year Consolidated Results Forecasts for the fiscal year ending March 31, 2022)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (Published August 3, 2021)	(Millions of yen) 275,000	(Millions of yen) 28,600	(Millions of yen) 29,000	(Millions of yen) 13,400	(Yen) 67.78
Revised forecast (B)	289,000	33,400	33,800	16,100	81.43
Difference (B – A)	14,000	4,800	4,800	2,700	—
Difference (%)	5.1	16.8	16.6	20.1	—
Reference: Business results for previous fiscal year (Ended March 31, 2021)	278,443	21,595	21,929	10,574	53.48

2. Consolidated Quarterly Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2021	As of Sept. 30, 2021
Assets		
Current assets		
Cash and deposits	66,238	71,250
Notes and accounts receivable-trade	61,954	65,699
Securities	1,145	980
Merchandise and finished goods	41,115	44,268
Work in process	1,924	2,318
Raw materials and supplies	6,084	6,685
Other	5,161	7,154
Allowance for doubtful accounts	(516)	(478)
Total current assets	183,108	197,879
Noncurrent assets		
Property, plant and equipment	74,740	80,228
Intangible assets		
Goodwill	10,142	10,299
Other	5,746	5,645
Total intangible assets	15,889	15,945
Investments and other assets		
Investment securities	27,924	28,425
Other	5,324	5,683
Allowance for doubtful accounts	(69)	(64)
Total investments and other assets	33,180	34,045
Total noncurrent assets	123,810	130,218
Total assets	306,918	328,097

(Millions of Yen)

	As of Mar. 31, 2021	As of Sept. 30, 2021
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,481	17,919
Short-term loans payable	5,166	5,035
Current portion of bonds	—	10,000
Accrued alcohol tax	6,890	6,440
Accrued expenses	6,455	4,275
Income taxes payable	4,021	4,971
Provision	4,914	3,762
Other	12,340	21,231
Total current liabilities	56,269	73,636
Noncurrent liabilities		
Bonds payable	20,000	10,000
Long-term loans payable	15,465	15,262
Lease obligations	3,122	3,216
Net defined benefit liability	9,274	9,256
Long-term deposits received	5,136	5,091
Other	6,114	5,840
Total noncurrent liabilities	59,113	48,665
Total liabilities	115,383	122,302
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,292	2,348
Retained earnings	135,184	139,215
Treasury stock	(1,682)	(1,682)
Total shareholders' equity	149,020	153,107
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	11,370	11,726
Deferred gains or losses on hedges	193	203
Foreign currency translation adjustment	(2,840)	2,133
Remeasurements of defined benefit plans	(859)	(786)
Total accumulated other comprehensive income	7,863	13,277
Noncontrolling interests	34,650	39,410
Total net assets	191,535	205,795
Total liabilities and net assets	306,918	328,097

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income**(Consolidated Statements of Income)****(For the Six Months Ended September 30, 2021 and 2020)**

(Millions of Yen)

	FY2021 (Apr. 1, 2020 – Sept. 30, 2020)	FY2022 (Apr. 1, 2021 – Sept. 30, 2021)
Net sales	127,784	141,213
Cost of sales	76,361	86,872
Gross profit	51,422	54,340
Selling, general and administrative expenses	45,639	32,724
Operating income	5,782	21,616
Nonoperating income		
Dividends income	283	311
Other	348	357
Total nonoperating income	632	669
Nonoperating expenses		
Interest expenses	176	160
Other	298	239
Total nonoperating expenses	474	400
Ordinary income	5,940	21,884
Extraordinary income		
National subsidies	—	1,188
Other	3	180
Total extraordinary income	3	1,368
Extraordinary loss		
Loss on tax purpose reduction entry of non-current assets	—	1,188
Loss on voluntary product recall	—	1,567
Loss on liquidation of business	464	—
Other	152	97
Total extraordinary losses	617	2,853
Income before income taxes	5,326	20,400
Income taxes-current	2,087	6,396
Income taxes-deferred	(189)	(354)
Total income taxes	1,898	6,041
Net income	3,428	14,358
Net income attributable to the noncontrolling interest	666	4,308
Net income attributable to owners of the parent	2,761	10,050

(Consolidated Statements of Comprehensive Income)
(For the Six Months Ended September 30, 2021 and 2020)

(Millions of Yen)

	FY2021 (Apr. 1, 2020 – Sept. 30, 2020)	FY2022 (Apr. 1, 2021 – Sept. 30, 2021)
Net income	3,428	14,358
Other comprehensive income		
Valuation difference on available-for-sale securities	1,345	355
Deferred gains or losses on hedges	(40)	10
Foreign currency translation adjustment	(2,316)	6,249
Remeasurements of defined benefit plans	16	81
Total other comprehensive income	(995)	6,697
Comprehensive income	2,433	21,056
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	2,248	15,464
Comprehensive income attributable to noncontrolling interest	184	5,591

(3) Consolidated Statements of Cash Flows

(Millions of Yen)

	FY2021 (Apr. 1, 2020 – Sept. 30, 2020)	FY2022 (Apr. 1, 2021 – Sept. 30, 2021)
Net cash provided by (used in) operating activities		
Income before income taxes	5,326	20,400
Depreciation and amortization	3,997	4,061
Loss on liquidation of business	464	–
Amortization of goodwill	432	432
Increase (decrease) in provision	(133)	(1,169)
Interest and dividends income	(370)	(381)
Interest expenses	176	160
Decrease (increase) in notes and accounts receivable-trade	2,168	(2,850)
Decrease (increase) in inventories	(3,041)	(2,472)
Increase (decrease) in notes and accounts payable-trade	(1,721)	1,008
Increase (decrease) in accrued consumption taxes	801	(1,316)
Other, net	189	(628)
Subtotal	8,290	17,244
Interest and dividends income received	393	411
Interest expenses paid	(196)	(162)
Income taxes paid	(2,406)	(6,365)
Subsidies received	–	671
Net cash provided by (used in) operating activities	6,081	11,798
Net cash provided by (used in) investing activities		
Payments into time deposits	(2,042)	(10,757)
Proceeds from withdrawal of time deposits	3,507	2,119
Proceeds from sales and redemption of securities	4,457	–
Purchase of property, plant and equipment and intangible assets	(8,821)	(6,827)
Subsidies received	–	3,349
Other, net	(203)	49
Net cash provided by (used in) investing activities	(3,102)	(12,066)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term borrowings	806	(330)
Proceeds from long-term borrowings	10,098	–
Redemption of bonds	(5,000)	–
Proceeds from issuance of commercial papers	5,000	–
Redemption of commercial papers	(5,000)	–
Cash dividends paid	(3,947)	(4,144)
Dividends paid to noncontrolling interests	(388)	(753)
Repayments of lease obligations	(333)	(348)
Other, net	(32)	(43)
Net cash provided by (used in) financing activities	1,202	(5,620)
Effect of exchange rate change on cash and cash equivalents	(471)	1,802
Net increase (decrease) in cash and cash equivalents	3,709	(4,085)
Cash and cash equivalents at beginning of period	44,541	62,860
Cash and cash equivalents at end of period	48,250	58,775

(4) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Changes in Accounting Policies)

(Application of Accounting Standard for Revenue Recognition, etc.)

The Company adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29, March 31, 2020, hereinafter referred to as the "Accounting Standard for Revenue Recognition"), etc. from the beginning of the three months ended June 30, 2021 and recognized revenue when control of promised goods or services is transferred to customers in an amount that is expected to be received in exchange for those goods or services. As a result, consideration paid to customers, which was previously treated as SG&A expenses, is deducted from net sales. In addition, an amount that is expected to be paid to customers after the balance sheet date, which was previously presented as part of "accrued expenses" and part of "provision" under "current liabilities," is included in "other" under "current liabilities" as refund liabilities.

With regard to the application of the Accounting Standard for Revenue Recognition, etc., in accordance with the transitional treatment stipulated in the provisions of paragraph 84 of the Accounting Standard for Revenue Recognition, the cumulative effect of retrospectively applying the new accounting policy prior to the beginning of the three months ended June 30, 2021 was added to or deducted from retained earnings at the beginning of the three months ended June 30, 2021, and a new accounting policy was applied from the beginning balance of the three months ended June 30, 2021.

As a result, in the six months ended September 30, 2021, net sales and SG&A expenses each decreased by ¥13,929 million. There was no impact on operating income, ordinary income, or income before income taxes. In addition, retained earnings at the beginning of the fiscal year ending March 31, 2022 decreased by ¥1,867 million, and refund liabilities included in "other" under current liabilities as of September 30, 2021 were ¥5,690 million.

In accordance with the transitional treatment stipulated in Paragraph 28-15 of the "Accounting Standard for Quarterly Financial Reporting" (ASBJ Statement No. 12, March 31, 2020), information on breakdown of revenue from contracts with customers for the six months ended September 30, 2020 is not stated.

(Application of Accounting Standard for Fair Value Measurement)

The Company adopted the "Accounting Standard for Fair Value Measurement" (ASBJ Statement No. 30, July 4, 2019, hereinafter referred to as the "Accounting Standard for Fair Value Measurement"), etc. from the beginning of the three months ended June 30, 2021, and decided to apply new accounting policies prescribed in the Accounting Standard for Fair Value Measurement in the future, in accordance with the transitional treatment as stipulated in Paragraph 19 of the Accounting Standard for Fair Value Measurement and Paragraph 44-2 of the "Accounting Standards for Financial Instruments" (ASBJ Statement No. 10, July 4, 2019). The application of these standards does not affect the consolidated quarterly financial statements for the six months ended September 30, 2021.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2020 to September 30, 2020)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	73,901	31,151	17,393	122,446	5,337	127,783	0	127,784
Intersegment	263	134	0	398	8,848	9,246	(9,246)	-
Total	74,164	31,286	17,393	122,844	14,186	137,030	(9,246)	127,784
Segment income (loss)	1,626	(396)	3,736	4,966	847	5,814	(31)	5,782

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥29 million and loss of the Company not allocated to business segments of ¥60 million.

3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

The Company posted a ¥365 million impairment loss in line with the liquidation of the next-generation sequencing library manufacturing equipment-related business, in the “Takara Bio Group” segment. This impairment loss is posted as “loss on liquidation of business” under extraordinary loss, together with related loss.

II. Period under Review (From April 1, 2021, to September 30, 2021)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	57,202	46,564	31,551	135,318	5,895	141,213	-	141,213
Intersegment	431	170	0	601	8,729	9,331	(9,331)	-
Total	57,633	46,734	31,551	135,919	14,624	150,544	(9,331)	141,213
Segment income	2,270	4,304	14,105	20,680	1,029	21,709	(93)	21,616

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business.

2. The adjustment to segment income of ¥(93) million comprises intersegment eliminations of ¥2 million and loss of the Company not allocated to business segments of ¥96 million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Changes in Reported Segment, etc.

As described in “(Changes in Accounting Policies)”, the Company adopted the “Accounting Standard for Revenue Recognition,” (ASBJ Statement No. 29, March 31, 2020), etc. from the beginning of the three months ended June 30, 2021, and changed the accounting method for revenue recognition. Accordingly, the measurement method of income or loss by business segment has also been changed.

As a result of these changes, compared with the amounts calculated by the conventional accounting method, net sales of Takara Shuzo in the six months ended September 30, 2021 decreased by ¥13,915 million, while net sales of the Takara Shuzo International Group decreased by ¥13 million.

3. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

(Revenue Recognition)

Information on breakdown of revenue from contracts with customers

Period under Review (From April 1, 2021, to September 30, 2021)

(Millions of yen)

	Reported Segment				Other (Note)	Total
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal		
Alcoholic Beverages Business	57,202	6,155	-	63,358	2,029	65,387
Japanese Food Wholesales Business in overseas markets	-	40,408	-	40,408	-	40,408
Bio	-	-	31,551	31,551	-	31,551
Other	-	-	-	-	3,562	3,562
Revenue earned from contracts with customers	57,202	46,564	31,551	135,318	5,592	140,910
Other revenue	-	-	-	-	302	302
Net sales to external customers	57,202	46,564	31,551	135,318	5,895	141,213

Note: “Other” includes business segments that are not part of reported segments, such as the import and sale of wine, the real estate rental business, and the transportation business.

(Significant Subsequent Events)

(Termination of significant contract)

At a meeting of the Board of Directors held on November 9, 2021, Takara Bio Inc. (“Takara Bio”), a consolidated subsidiary of the Company, resolved to terminate agreements on co-development and exclusive marketing of HF10* and CD19CAR (the “Agreements”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), and, with the consent of both companies, terminated the Agreements as of November 9, 2021.

(1) Reasons for the termination

1) Oncolytic Virus, HF10*

Based on the results of a Phase I clinical trial for pancreatic cancer, Takara Bio and Otsuka examined the development plan for pancreatic cancer and other types of cancer, and decided to terminate the agreement by considering the time required for future development and other factors.

2) CD19 CAR gene therapy product

Because of the prolonged Phase I/II trial for adult acute lymphoblastic leukemia and the developing status of other related investigational products, we decided to terminate the agreement.

(2) Name of the other party in the Agreements

Otsuka Pharmaceutical Co., Ltd.

(3) Date of termination of the Agreements

November 9, 2021

(4) Details of the Agreements

1) Oncolytic Virus, HF10*

Takara Bio and Otsuka co-develop the gene therapy product by using HF10 hereinafter the product in Japan. Takara Bio grant Otsuka exclusive rights to market the product for all indications in Japan, and receive an upfront payment, milestone payments based on the progress of development and lump-sum payment based on the achievement of net sales targets. In addition, Takara Bio retain the rights to manufacture the product for clinical trials and the further commercialization and supply Otsuka on a chargeable basis.

2) CD19 CAR gene therapy

Takara Bio and Otsuka co-develop the CD19 CAR gene therapy product in Japan. Takara Bio grants Otsuka exclusive rights to market the product for all indications in Japan and the first refusal right for nine Asian countries outside Japan. Takara Bio receive an upfront payment, milestone payments based on the progress of development. In addition, Takara Bio retain the rights to manufacture the product for clinical trials and the further commercialization and supply Otsuka on a chargeable basis.

(5) Significant impact of the termination of the Agreements on operating activities, etc.

The technical, intellectual property and other rights of the Oncolytic Virus and the CD19 CAR gene therapy product licensed to Otsuka under the agreements are returned to Takara Bio with the termination. The milestone payments, lump-sum payments and the sales revenues on the further commercial supply will not occur.

* Generic name at the time of agreement, canerpaturev (abbreviation C-REV)

2022年3月期
第2四半期決算短信補足資料
Supplement for the Consolidated Financial Statements
for the Second Quarter Ended September 30, 2021

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
 - ① グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)
 - ② 要約貸借対照表
Consolidated Balance Sheets (Summary)
2. 宝酒造
Takara Shuzo
要約損益計算書
Statements of Income (Summary)
3. 宝酒造インターナショナルグループ
Takara Shuzo International Group
要約損益計算書
Statements of Income (Summary)
4. タカラバイオグループ
Takara Bio Group
要約損益計算書
Statements of Income (Summary)
5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group
6. 2022年3月期第2四半期 参考資料
Reference Data for the Second Quarter Ended September 30, 2020
7. 2022年3月期第2四半期業績【「収益認識に関する会計基準」等適用前】
Results for the six months ended September 30, 2021 based on before the application of
【Accounting Standard for Revenue Recognition】
8. 2022年3月期 業績予想
Financial forecast for the year ending March 31, 2022
9. 2022年3月期 参考資料
Reference Data for the year ending March 31, 2022
10. 2022年3月期 業績予想【「収益認識に関する会計基準」等適用前】
Financial forecast for the year ending March 31, 2022 based on before the application of
【Accounting Standard for Revenue Recognition】

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.

TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社 財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124 FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	2021年3月期 第2四半期累計	2022年3月期 第2四半期累計 Apr. 1, 2021 - Sep. 30, 2021	対前期 Change from FY2021(1Q-2Q)		対8/3予想 Change from forecast announced Aug. 2021		
	実績(a) FY2021(1Q-2Q) Actual (a)	8/3予想(b) FY2022(1Q-2Q) Forecast announced Aug. 2021 (b)	実績(c) FY2022(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)
宝酒造 Takara Shuzo	74,164	58,793	57,633	△ 16,531	△ 22.3%	△ 1,159	△ 2.0%
宝酒造インターナショナルグループ Takara Shuzo International Group	31,286	46,593	46,734	15,448	49.4%	141	0.3%
タカラバイオ グループ Takara Bio Group	17,393	29,700	31,551	14,158	81.4%	1,851	6.2%
その他 Other	14,186	14,455	14,624	438	3.1%	169	1.2%
調整額 Adjustment	△ 9,246	△ 9,541	△ 9,331	△ 84	—	209	—
売上高 Net sales	127,784	140,000	141,213	13,429	10.5%	1,213	0.9%
売上原価 Cost of sales	76,361	88,500	86,872	10,511	13.8%	△ 1,627	△ 1.8%
売上総利益 Gross profit	51,422	51,500	54,340	2,917	5.7%	2,840	5.5%
運送費、保管料 Transportation and storage	5,248	5,800	5,752	504	9.6%	△ 47	△ 0.8%
広告宣伝費 Advertising	992	1,200	1,122	130	13.1%	△ 77	△ 6.4%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	16,885	1,900	1,697	△ 15,187	△ 89.9%	△ 202	△ 10.7%
研究開発費 Research and development	2,579	2,900	2,847	267	10.4%	△ 52	△ 1.8%
管理費、その他 Other, net	19,935	21,600	21,305	1,370	6.9%	△ 294	△ 1.4%
販売費及び一般管理費 SG&A expenses	45,639	33,400	32,724	△ 12,915	△ 28.3%	△ 675	△ 2.0%
宝酒造 Takara Shuzo	1,626	1,984	2,270	644	39.6%	286	14.4%
宝酒造インターナショナルグループ Takara Shuzo International Group	△ 396	3,960	4,304	4,700	—	344	8.7%
タカラバイオ グループ Takara Bio Group	3,736	11,400	14,105	10,368	277.5%	2,705	23.7%
その他 Other	847	908	1,029	181	21.4%	121	13.4%
調整額 Adjustment	△ 31	△ 151	△ 93	△ 62	—	57	—
営業利益(△:損失) Operating income(△:loss)	5,782	18,100	21,616	15,833	273.8%	3,516	19.4%
受取利息・配当金 Interest and Dividends income	370	400	381	10	2.9%	△ 18	△ 4.7%
その他営業外収益 Other, net	261	200	287	25	9.9%	87	43.9%
営業外収益 Non-operating income	632	600	669	36	5.8%	69	11.5%
支払利息 Interest and discounts expenses	176	100	160	△ 15	△ 8.8%	60	60.7%
その他営業外費用 Other, net	298	400	239	△ 58	△ 19.7%	△ 160	△ 40.0%
営業外費用 Non-operating expenses	474	500	400	△ 74	△ 15.7%	△ 99	△ 19.9%
経常利益(△:損失) Ordinary income(△:loss)	5,940	18,200	21,884	15,944	268.4%	3,684	20.2%
特別利益 Extraordinary income	3	3,100	1,368	1,365	43,214.5%	△ 1,731	△ 55.8%
特別損失 Extraordinary loss	617	4,700	2,853	2,236	362.3%	△ 1,846	△ 39.3%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	5,326	16,600	20,400	15,073	283.0%	3,800	22.9%
法人税、住民税及び事業税 Current income taxes	2,087	5,400	6,396	4,309	206.4%	641	11.9%
法人税等調整額 Deferred income taxes	△ 189		△ 354	△ 165	—		
四半期純利益(△:損失) Net income(△:loss)	3,428	11,200	14,358	10,930	318.8%	3,158	28.2%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	666	3,400	4,308	3,641	546.4%	908	26.7%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	2,761	7,800	10,050	7,288	263.9%	2,250	28.9%
設備投資額(有形・無形) Capital expenditures	8,448		8,811	362	4.3%		
減価償却費(有形・無形) Depreciation and Amortization	3,997	4,100	4,061	64	1.6%	△ 38	△ 0.9%
のれん償却額 Amortization of goodwill	432	400	432	△ 0	△ 0.1%	32	8.1%
営業外収益 Non-operating income	受取配当金 311 など Dividend income 311, etc.						
営業外費用 Non-operating expenses	支払利息 115 など Interest expense 115, etc.						
特別利益 Extraordinary income	国庫補助金 1,188 など National subsidies 1,188, etc.						
特別損失 Extraordinary loss	固定資産圧縮損 1,188、製品自主回収関連損失 1,567 など Loss on tax purpose reduction entry of non-current assets 1,188, Loss on product recall 1,567, etc.						

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets

(百万円 :Millions of Yen)

	2021年 3月期末 As of Mar. 31, 2021	2022年3月期 第2四半期末 As of Sep. 30, 2021	増減 Change	主な増減理由 Reference
(流動資産) (Total current assets)	183,108	197,879	14,771	(億円 :One hundred millions of Yen)
現金及び預金 Cash and deposits	66,238	71,250	5,012	TH △32.4、TSI +25.0、TB +65.9
受取手形及び売掛金 Notes and accounts receivable-trade	61,954	65,699	3,744	TSI +28.4、TB +10.1
有価証券 Marketable securities	1,145	980	△ 164	
棚卸資産 Inventories	49,124	53,272	4,147	TS +11.6、TSI +15.1、TB +15.0
その他 Other current assets	5,161	7,154	1,993	
貸倒引当金 Allowance for doubtful accounts	△ 516	△ 478	37	
(固定資産) (Total fixed assets)	123,810	130,218	6,408	
[有形固定資産] [Property, plant and equipment]	74,740	80,228	5,487	
建物及び構築物 Buildings and structures	25,959	26,734	774	
機械装置及び運搬具 Machinery, equipment and vehicles	15,410	15,455	44	
土地 Land	20,640	20,971	330	
その他 Other property, plant and equipment	12,729	17,067	4,337	
[無形固定資産] [Intangible fixed assets]	15,889	15,945	55	
のれん Goodwill	10,142	10,299	156	
その他 Other intangible fixed assets	5,746	5,645	△ 101	
[投資その他の資産] [Investments and other assets]	33,180	34,045	864	
投資有価証券 Investment securities	27,924	28,425	501	
その他 Other assets	5,324	5,683	358	
貸倒引当金 Allowance for doubtful accounts	△ 69	△ 64	4	
資産合計 Total assets	306,918	328,097	21,179	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産の部 :Liabilities and net assets

(百万円 :Millions of Yen)

	2021年 3月期末 As of Mar. 31, 2021	2022年3月期 第2四半期末 As of Sep. 30, 2021	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	56,269	73,636	17,367	(億円 :One hundred millions of Yen)
支払手形及び買掛金 Notes and accounts payable-trade	16,481	17,919	1,438	
短期借入金 Short-term loans payable	5,166	5,035	△ 131	
1年内償還の社債 Current portion of bonds	—	10,000	10,000	TH +100.0(第13回普通社債 2022年4月償還) (#13SB Redemption Apr. 2022) (第14回普通社債 2022年4月償還) (#14SB Redemption Apr. 2022)
未払酒税 Accrued alcohol tax	6,890	6,440	△ 449	
未払費用 Accrued expenses	6,455	4,275	△ 2,179	
販売促進引当金 Reserve for sales promotion expenses	2,049	—	△ 2,049	
その他 Other current liabilities	19,226	29,965	10,738	
(固定負債) (Total non-current liabilities)	59,113	48,665	△ 10,447	
社債 Bonds payable	20,000	10,000	△ 10,000	TH △100.0(第13回普通社債 2022年4月償還) (#13SB Redemption Apr. 2022) (第14回普通社債 2022年4月償還) (#14SB Redemption Apr. 2022)
長期借入金 Long-term loans payable	15,465	15,262	△ 203	
退職給付に係る負債 Net defined benefit liability	9,274	9,256	△ 17	
預り金 Deposits from customers	5,136	5,091	△ 45	
その他 Other non-current liabilities	9,236	9,056	△ 180	
負債合計 Total liabilities	115,383	122,302	6,919	
資本金 Capital stock	13,226	13,226	—	
資本剰余金 Capital surplus	2,292	2,348	56	
利益剰余金 Retained earnings	135,184	139,215	4,030	
自己株式 Treasury stock	△ 1,682	△ 1,682	△ 0	
(株主資本) (Total owner's equity)	149,020	153,107	4,086	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	11,370	11,726	355	
繰延ヘッジ損益 Deferred gains or losses on hedges	193	203	10	
為替換算調整勘定 Translation adjustments	△ 2,840	2,133	4,974	TSI+35.7、TB+14.0 USD=110.61JPY, EUR=131.63JPY, GBP=153.22JPY (Jun. 2021) USD=103.52JPY, EUR=126.99JPY, GBP=139.87JPY (Dec.2020)
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 859	△ 786	73	
(その他の包括利益累計額) (Total valuation and translation adjustments)	7,863	13,277	5,413	
(非支配株主持分) (Noncontrolling interests)	34,650	39,410	4,759	
純資産合計 Total net assets	191,535	205,795	14,260	
負債純資産合計 Total liabilities and net assets	306,918	328,097	21,179	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2021年3月期 第2四半期累計		2022年3月期 第2四半期累計 Apr. 1, 2021 - Sep. 30, 2021		対前期 Change from FY2021(1Q-2Q)		対8/3予想 Change from forecast announced Aug. 2021	
	実績(a) FY2021(1Q-2Q) Actual (a)	8/3予想(b) FY2022(1Q-2Q) Forecast announced May 2020 (b)	実績(c) FY2022(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)	
焼酎 Shochu	24,284	19,647	19,315	△ 4,968	△ 20.5%	△ 331	△ 1.7%	
清酒 Sake	6,792	4,835	4,718	△ 2,073	△ 30.5%	△ 116	△ 2.4%	
ソフトアルコール飲料 Light-alcohol refreshers	24,024	19,419	18,808	△ 5,215	△ 21.7%	△ 610	△ 3.1%	
その他酒類 Other liquors	2,684	2,621	2,529	△ 154	△ 5.8%	△ 91	△ 3.5%	
本みりん Hon Mirin	6,288	4,143	4,258	△ 2,030	△ 32.3%	115	2.8%	
その他調味料 Other seasonings	4,976	4,064	4,079	△ 897	△ 18.0%	15	0.4%	
原料用アルコール等 Raw alcohol	5,114	4,064	3,922	△ 1,191	△ 23.3%	△ 141	△ 3.5%	
売上高 Net sales	74,164	58,793	57,633	△ 16,531	△ 22.3%	△ 1,159	△ 2.0%	
売上原価 Cost of sales	45,183	44,421	43,341	△ 1,841	△ 4.1%	△ 1,079	△ 2.4%	
売上総利益 Gross profit	28,981	14,372	14,291	△ 14,690	△ 50.7%	△ 80	△ 0.6%	
運送費、保管料 Transportation and storage	4,013	4,059	3,977	△ 36	△ 0.9%	△ 81	△ 2.0%	
広告宣伝費 Advertising	924	1,165	1,052	127	13.8%	△ 112	△ 9.7%	
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	16,429	1,133	1,059	△ 15,369	△ 93.5%	△ 73	△ 6.5%	
研究開発費 Research and development	172	185	183	11	6.6%	△ 1	△ 0.9%	
管理費、その他 Other, net	5,815	5,846	5,748	△ 67	△ 1.2%	△ 97	△ 1.7%	
販売費及び一般管理費 SG&A expenses	27,355	12,388	12,020	△ 15,334	△ 56.1%	△ 367	△ 3.0%	
営業利益(△:損失) Operating income(△:loss)	1,626	1,984	2,270	644	39.6%	286	14.4%	
営業外収益 Non-operating income	145	150	178	32	22.2%	28	18.7%	
営業外費用 Non-operating expenses	146	147	127	△ 18	△ 12.8%	△ 19	△ 13.1%	
経常利益(△:損失) Ordinary income(△:loss)	1,625	1,987	2,321	695	42.8%	334	16.8%	
特別利益 Extraordinary gain	—	100	110	110	—	10	10.6%	
特別損失 Extraordinary loss	37	1,630	1,622	1,584	4,221.9%	△ 7	△ 0.5%	
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	1,588	457	809	△ 778	△ 49.0%	352	77.1%	
法人税、住民税及び事業税 Current income taxes	617	169	459	△ 158	△ 25.7%	87	51.9%	
法人税等調整額 Deferred income taxes	△ 104		△ 202	△ 97	—			
四半期純利益(△:損失) Net income(△:loss)	1,074	288	552	△ 521	△ 48.6%	264	91.9%	
設備投資額(有形・無形) Capital expenditures	477		500	22	4.8%			
減価償却費(有形・無形) Depreciation and Amortization	1,397	1,290	1,257	△ 140	△ 10.0%	△ 32	△ 2.5%	

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2021年3月期 第2四半期累計	2022年3月期 第2四半期累計 Apr. 1, 2021 - Sep. 30, 2021		対前期 Change from FY2021(1Q-2Q)		対8/3予想 Change from forecast announced Aug. 2021	
	実績(a) FY2021(1Q-2Q) Actual (a)	8/3予想(b) FY2022(1Q-2Q) Forecast announced May 2020 (b)	実績(c) FY2022(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)
海外酒類事業 Overseas Alcoholic beverages business	4,574	6,932	7,005	2,430	53.1%	73	1.1%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	27,099	40,349	40,410	13,311	49.1%	61	0.2%
その他 Other	35	29	29	△ 6	△ 16.9%	0	2.5%
連結消去 Elimination	△ 424	△ 717	△ 710	△ 286	—	6	—
売上高 Net sales	31,286	46,593	46,734	15,448	49.4%	141	0.3%
売上原価 Cost of sales	22,140	31,868	31,747	9,606	43.4%	△ 120	△ 0.4%
売上総利益 Gross profit	9,145	14,725	14,987	5,841	63.9%	262	1.8%
運送費、保管料 Transportation and storage	1,011	1,517	1,517	505	50.0%	0	0.1%
広告宣伝費 Advertising	33	43	39	6	18.1%	△ 3	△ 7.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	223	379	355	132	59.4%	△ 23	△ 6.1%
管理費、その他 Other, net	8,273	8,826	8,769	496	6.0%	△ 56	△ 0.6%
販売費及び一般管理費 SG&A expenses	9,541	10,765	10,682	1,140	12.0%	△ 82	△ 0.8%
海外酒類事業 Overseas Alcoholic beverages business	888	2,089	2,145	1,257	141.5%	56	2.7%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 530	2,631	2,904	3,434	—	273	10.4%
その他 Other	△ 531	△ 517	△ 491	39	—	25	—
連結消去 Elimination	△ 224	△ 243	△ 254	△ 30	—	△ 11	—
営業利益(△:損失) Operating income(△:loss)	△ 396	3,960	4,304	4,700	—	344	8.7%
営業外収益 Non-operating income	88	89	81	△ 7	△ 7.9%	△ 7	△ 8.2%
営業外費用 Non-operating expenses	141	152	159	17	12.6%	7	4.9%
経常利益(△:損失) Ordinary income(△:loss)	△ 449	3,897	4,226	4,676	—	329	8.5%
特別利益 Extraordinary gain	1	—	2	0	45.4%	2	—
特別損失 Extraordinary loss	35	13	6	△ 28	△ 82.0%	△ 6	△ 51.5%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	△ 482	3,884	4,222	4,705	—	338	8.7%
法人税、住民税及び事業税 Current income taxes	△ 66	1,423	1,108	1,174	—	△ 259	△ 18.3%
法人税等調整額 Deferred income taxes	4		55	50	1,235.8%		
四半期純利益(△:損失) Net income(△:loss)	△ 420	2,461	3,059	3,480	—	598	24.3%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	△ 239	281	349	589	—	68	24.4%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	△ 181	2,180	2,709	2,891	—	529	24.3%
設備投資額(有形・無形) Capital expenditures	1,631		462	△ 1,169	△ 71.7%		
減価償却費(有形・無形) Depreciation and Amortization	696	825	837	140	20.2%	12	1.5%
のれん償却額 Amortization of goodwill	186	187	187	0	0.4%	0	0.1%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2021年3月期 第2四半期累計		2022年3月期 第2四半期累計 Apr. 1, 2021 - Sep. 30, 2021		対前期 Change from FY2021(1Q-2Q)		対8/3予想 Change from forecast announced Aug. 2021	
	実績(a) FY2021(1Q-2Q) Actual (a)	8/3予想(b) FY2022(1Q-2Q) Forecast announced Aug. 2021 (b)	実績(c) FY2022(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)	
試薬 Reagents	13,336	24,058	25,966	12,629	94.7%	1,908	7.9%	
機器 Instruments	466	790	712	245	52.6%	△ 78	△ 9.9%	
受託 CDMO	3,373	4,727	4,732	1,358	40.3%	5	0.1%	
遺伝子医療 Gene Therapy	215	123	140	△ 75	△ 35.0%	16	13.4%	
売上高 Net sales	17,393	29,700	31,551	14,158	81.4%	1,851	6.2%	
売上原価 Cost of sales	5,565	8,749	8,056	2,490	44.7%	△ 693	△ 7.9%	
売上総利益 Gross profit	11,827	20,950	23,495	11,667	98.6%	2,544	12.1%	
運送費、保管料 Transportation and storage	336	425	406	69	20.8%	△ 19	△ 4.6%	
広告宣伝費 Advertising	31	29	28	△ 2	△ 8.4%	△ 0	△ 2.7%	
販売促進費 Sales promotion	276	434	305	29	10.8%	△ 128	△ 29.6%	
研究開発費 Research and development	2,403	2,689	2,659	255	10.6%	△ 30	△ 1.1%	
管理費、その他 Other, net	5,044	5,970	5,989	945	18.7%	18	0.3%	
販売費及び一般管理費 SG&A expenses	8,090	9,550	9,389	1,298	16.1%	△ 160	△ 1.7%	
営業利益(△:損失) Operating income(△:loss)	3,736	11,400	14,105	10,368	277.5%	2,705	23.7%	
営業外収益 Non-operating income	143	135	179	36	25.3%	43	32.3%	
営業外費用 Non-operating expenses	59	135	43	△ 16	△ 27.7%	△ 92	△ 68.2%	
経常利益(△:損失) Ordinary income(△:loss)	3,820	11,400	14,241	10,421	272.8%	2,841	24.9%	
特別利益 Extraordinary income	1	2,992	1,188	1,187	98,936.5%	△ 1,803	△ 60.3%	
特別損失 Extraordinary loss	539	3,021	1,227	687	127.6%	△ 1,794	△ 59.4%	
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	3,281	11,370	14,203	10,921	332.8%	2,832	24.9%	
法人税、住民税及び事業税 Current income taxes	1,203	3,426	4,401	3,197	265.8%	721	21.0%	
法人税等調整額 Deferred income taxes	△ 212		△ 253	△ 40	—			
四半期純利益(△:損失) Net income(△:loss)	2,291	7,943	10,054	7,763	338.8%	2,111	26.6%	
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	16	43	45	28	170.1%	2	5.4%	
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	2,274	7,900	10,009	7,734	340.1%	2,109	26.7%	
設備投資額(有形・無形) Capital expenditures	6,087		7,676	1,588	26.1%			
減価償却費(有形・無形) Depreciation and Amortization	1,631	1,736	1,670	38	2.4%	△ 66	△ 3.8%	
のれん償却額 Amortization of goodwill	246	245	245	△ 0	△ 0.4%	—	—	

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2017年3月期 第2四半期 FY2017 (1Q-2Q)	2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	前対比 Change from FY2021(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	107,509	128,855	133,987	137,502	127,784	141,213	13,429	10.5%
売上原価 Cost of sales (売上高原価率) (Ratio to Net sales)	64,073 59.6%	79,401 61.6%	81,332 60.7%	84,468 61.4%	76,361 59.8%	86,872 61.5%	10,511 +1.8pt	13.8% -
売上総利益 Gross profit	43,435	49,454	52,655	53,033	51,422	54,340	2,917	5.7%
販売費及び一般管理費 SG&A expenses (売上高販管費率) (Ratio to Net sales)	38,228 35.6%	43,326 33.6%	44,495 33.2%	45,410 33.0%	45,639 35.7%	32,724 23.2%	△ 12,915 -12.5pt	△ 28.3% -
営業利益(△:損失) Operating income(Δ:loss) (売上高営業利益率) (Ratio to Net Sales)	5,207 4.8%	6,128 4.8%	8,159 6.1%	7,623 5.5%	5,782 4.5%	21,616 15.3%	15,833 +10.8pt	273.8% -
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p. (売上高販管費率) (Ratio to Net sales)	16,382 15.2%	16,328 12.7%	16,459 12.3%	17,011 12.4%	16,885 13.2%	1,697 1.2%	△ 15,187 -12.0pt	△ 89.9% -
研究開発費 R&D expenses (売上高研究開発費率) (Ratio to Net sales)	2,093 1.9%	2,505 1.9%	2,286 1.7%	2,057 1.5%	2,579 2.0%	2,847 2.0%	267 -0.0pt	10.4% -
設備投資額(有形・無形) Capital expenditures	1,909	2,451	2,603	8,421	8,448	8,811	362	4.3%
減価償却費(有形・無形) Depreciation and Amortization	2,492	3,157	3,183	3,364	3,997	4,061	64	1.6%
のれん償却額 Amortization of goodwill	238	407	429	424	432	432	△ 0	△ 0.1%

宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2017年3月期 第2四半期 FY2017 (1Q-2Q)	2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	前対比 Change from FY2021(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	70,429	71,973	73,259	75,135	74,164	57,633	△ 16,531	△ 22.3%
売上原価 Cost of sales (売上高原価率) (Ratio to Net sales)	42,478 60.3%	43,360 60.2%	44,144 60.3%	45,586 60.7%	45,183 60.9%	43,341 75.2%	△ 1,841 +14.3pt	△ 4.1% -
売上総利益 Gross profit	27,950	28,613	29,115	29,549	28,981	14,291	△ 14,690	△ 50.7%
販売費及び一般管理費 SG&A expenses (売上高販管費率) (Ratio to Net sales)	26,499 37.6%	26,621 37.0%	26,839 36.6%	27,467 36.6%	27,355 36.9%	12,020 20.9%	△ 15,334 -16.0pt	△ 56.1% -
営業利益(△:損失) Operating income(Δ:loss) (売上高営業利益率) (Ratio to Net sales)	1,451 2.1%	1,991 2.8%	2,275 3.1%	2,082 2.8%	1,626 2.2%	2,270 3.9%	644 +1.7pt	39.6% -
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p. (売上高販管費率) (Ratio to Net sales)	15,754 22.4%	15,707 21.8%	15,845 21.6%	16,431 21.9%	16,429 22.2%	1,059 1.8%	△ 15,369 -20.3pt	△ 93.5% -
設備投資額(有形・無形) Capital expenditures	758	1,002	799	4,004	477	500	22	4.8%
減価償却費(有形・無形) Depreciation and Amortization	1,051	1,059	1,080	1,165	1,397	1,257	△ 140	△ 10.0%

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2017年3月期 第2四半期 FY2017 (1Q-2Q)	2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	前対比 Change from FY2021(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	15,137	33,822	37,527	40,477	31,286	46,734	15,448	49.4%
売上原価 Cost of sales (売上高原価率) (Ratio to Net sales)	10,085 66.6%	23,845 70.5%	26,329 70.2%	28,994 71.6%	22,140 70.8%	31,747 67.9%	9,606 -2.8pt	43.4% -
売上総利益 Gross profit	5,052	9,976	11,197	11,483	9,145	14,987	5,841	63.9%
販売費及び一般管理費 SG&A expenses (売上高販管費率) (Ratio to Net sales)	3,659 24.2%	7,753 22.9%	8,762 23.3%	9,918 24.5%	9,541 30.5%	10,682 22.9%	1,140 -7.6pt	12.0% -
営業利益(△:損失) Operating income(Δ:loss) (売上高営業利益率) (Ratio to Net sales)	1,393 9.2%	2,223 6.6%	2,434 6.5%	1,565 3.9%	△ 396 -	4,304 9.2%	4,700 -	- -
設備投資額(有形・無形) Capital expenditures	263	774	614	908	1,631	462	△ 1,169	△ 71.7%
減価償却費(有形・無形) Depreciation and Amortization	287	455	496	585	696	837	140	20.2%
のれん償却額 Amortization of goodwill	205	170	182	173	186	187	0	0.4%

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2017年3月期 第2四半期 FY2017 (1Q-2Q)	2018年3月期 第2四半期 FY2018 (1Q-2Q)	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	前対比 Change from FY2021(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	13,199	14,126	17,370	16,450	17,393	31,551	14,158	81.4%
売上原価 Cost of sales (売上高原価率) (Ratio to Net sales)	5,152 39.0%	5,965 42.2%	7,049 40.6%	6,121 37.2%	5,565 32.0%	8,056 25.5%	2,490 -6.5pt	44.7% -
売上総利益 Gross profit	8,046	8,160	10,321	10,329	11,827	23,495	11,667	98.6%
販売費及び一般管理費 SG&A expenses (売上高販管費率) (Ratio to Net sales)	6,669 50.5%	7,471 52.9%	7,697 44.3%	7,293 44.3%	8,090 46.5%	9,389 29.8%	1,298 -16.8pt	16.1% -
営業利益(△:損失) Operating income(Δ:loss) (売上高営業利益率) (Ratio to Net sales)	1,377 10.4%	688 4.9%	2,623 15.1%	3,035 18.5%	3,736 21.5%	14,105 44.7%	10,368 +23.2pt	277.5% -
研究開発費 R&D expenses (売上高研究開発費率) (Ratio to Net sales)	1,904 14.4%	2,297 16.3%	2,104 12.1%	1,858 11.3%	2,403 13.8%	2,659 8.4%	255 -5.4pt	10.6% -
設備投資額(有形・無形) Capital expenditures	573	439	1,068	3,190	6,087	7,676	1,588	26.1%
減価償却費(有形・無形) Depreciation and Amortization	856	1,247	1,336	1,352	1,631	1,670	38	2.4%
のれん償却額 Amortization of goodwill	83	236	247	250	246	245	△ 0	△ 0.4%

6. 2022年3月期第2四半期 参考資料 :Reference Data for the Second Quarter Ended September 30, 2021

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of overseas subsidiaries

(円 : Yen)

	2021年3月期 第2四半期累計		2022年3月期 第2四半期累計 Apr. 1, 2021 - Sep. 30, 2021		
	実績(a) FY2021(1Q-2Q) Actual (a)	8/3予想(b) FY2022(1Q-2Q) Forecast announced Aug. 2021 (b)	実績(c) FY2022(1Q-2Q) Actual (c)	前期差 Change(c-a)	予想差 Change(c-b)
	米ドル : US dollar	108.25	107.82	107.82	△ 0.43
ポンド : Pound	136.43	149.78	149.78	13.35	0.00
ユーロ : Euro	119.34	129.88	129.88	10.54	0.00
人民元 : Yuan	15.38	16.67	16.67	1.29	0.00
100ウォン : 100 Won	8.97	9.64	9.64	0.67	0.00
インドルピー : Rupee	1.46	1.47	1.47	0.01	0.00
スウェーデンクローナ : Sweden krona	11.20	12.82	12.82	1.62	0.00
シンガポールドル : Singapore dollar	77.41	80.90	80.90	3.49	0.00
オーストラリアドル : Australian dollar	71.16	83.13	83.13	11.97	0.00

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2021(1Q-2Q)	対8/3予想 Change from forecast announced Aug. 2021
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	2,627	—
うち宝酒造インターナショナルグループ Net sales of Takara Shuzo International Group	1,856	—
海外酒類事業 Overseas Alcoholic beverages business	209	—
海外日本食材卸事業 Japanese food wholesale business in overseas markets	1,646	—
その他 Other	—	—
連結消去 Elimination	0	—
うちタカラバイオグループ Net sales of Takara Bio Group	775	—
研究用試薬 Research reagents	740	—
理化学機器 Scientific instruments	8	—
受託サービス Contracted service	27	—
遺伝子医療 Gene Therapy	—	—

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2021年3月期第2四半期 実績 FY2021(1Q-2Q) Actual			2022年3月期第2四半期 実績 FY2022(1Q-2Q) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	74,164	—	—	57,633	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	31,286	31,139	99.5%	46,734	46,504	99.5%
タカラバイオグループ Takara Bio Group	17,393	10,487	60.3%	31,551	16,111	51.1%
その他および調整額 Other / Adjustment	4,939	—	—	5,293	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	127,784	41,626	32.6%	141,213	62,615	44.3%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2021年3月期第2四半期 実績 FY2021(1Q-2Q) Actual		2022年3月期第2四半期 実績 FY2022(1Q-2Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ/loss)	売上高 Net Sales	営業利益 Operating income(Δ/loss)
米国宝酒造 Takara Sake USA Inc.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	12,409	Δ 504	19,697	3,733
宝酒造食品 Takara Shuzo Foods Co.,Ltd.	千 元 :Thousands of Yuan 百万円 :Millions of Yen	17,380	Δ 466	28,240	1,933
トマーチン The Tomatin Distillery Co.,Ltd.	千 ポンド :Thousands of Pound 百万円 :Millions of Yen	8,707	2,290	13,889	5,629
エイジ・インターナショナル AGE INTERNATIONAL, INC.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	14,435	6,604	18,652	8,611
フーデックスグループ FOODEX Group	千 ユーロ :Thousands of Euro 百万円 :Millions of Yen	68,503	3,252	104,468	12,256
タザキフーズ TAZAKI FOODS LTD.	千 ポンド :Thousands of Pound 百万円 :Millions of Yen	18,748	230	23,083	1,451
ミュールチャルトレーディング Mutual Trading Co., Inc.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	132,081	Δ 8,906	189,089	5,914
ニッポンフード Nippon Food Supplies Company Pty Ltd	千 AUS ドル :Thousands of Australian dollar 百万円 :Millions of Yen	23,580	119	26,577	1,950
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百万円 :Millions of Yen	1,677	8	2,209	162
タカラバイオヨーロッパS.A.S.(連結) Takara Bio Europe S.A.S. Consolidated	千 ユーロ :Thousands of Euro 百万円 :Millions of Yen	16,302	1,764	32,364	6,352
宝生物工程(大連) Takara Biotechnology (Dalian) Co.,Ltd.	千 元 :Thousands of Yuan 百万円 :Millions of Yen	188,671	105,260	152,249	47,128
宝日医生物技術(北京) Takara Biomedical Technology (Beijing) Co., Ltd.	千 元 :Thousands of Yuan 百万円 :Millions of Yen	223,618	45,596	322,063	58,786
タカラコアバイオメディカル Takara Korea Biomedical Inc.	百万ウォン :Millions of Won 百万円 :Millions of Yen	6,563	1,108	6,273	1,041
タカラバイオDSSインド DSS Takara Bio India Private Limited	千 インドルピー :Thousands of Rupee 百万円 :Millions of Yen	154,548	30,951	470,318	83,145
タカラバイオUSA Takara Bio USA, Inc.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	45,533	814	59,052	7,102

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2021(1Q-2Q)			
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition	「収益認識に関する会計基準」 の適用による影響額 Effect of applying "Accounting Standards for Revenue Recognition"
売上総利益 計 Gross profit	Δ 14,690	Δ 1,022	+247	Δ 13,915
(主な内訳)				
焼酎 Shochu	Δ 4,927	Δ 42	Δ 28	Δ 4,857
清酒 Sake	Δ 1,606	Δ 286	+28	Δ 1,347
ソフトアルコール飲料 Light-alcohol refreshers	Δ 4,663	Δ 386	+29	Δ 4,306
本みりん Hon Mirin	Δ 2,144	+30	Δ 88	Δ 2,086
(参考)原価コストダウン Reference :Cost reduction	+147	※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「Δ」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

	2021年3月期第2四半期 実績 FY2021(1Q-2Q) Actual		2022年3月期第2四半期 実績 FY2022(1Q-2Q) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ/loss)	売上高 Net Sales	営業利益 Operating income(Δ/loss)
物流事業 Transportation	6,776	258	6,854	297
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	254	211	251	209
その他 Other	7,155	378	7,518	522
「その他」計 Total "Other"	14,186	847	14,624	1,029

7. 2022年3月期 第2四半期業績【「収益認識に関する会計基準」等適用前】

Results for the six months ended September 30, 2021 based on before the application of
【Accounting Standard for Revenue Recognition】

①宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期	対前期	
	第2四半期累計	第2四半期累計	Change from FY2021(1Q-2Q)	
	実績(a) FY2021(1Q-2Q) Actual (a)	実績(b) FY2022(1Q-2Q) Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
宝酒造 Takara Shuzo	74,164	71,549	△ 2,615	△ 3.5%
宝酒造インターナショナルグループ Takara Shuzo International Group	31,286	46,748	15,462	49.4%
タカラバイオ グループ Takara Bio Group	17,393	31,551	14,158	81.4%
その他 Other	14,186	14,624	438	3.1%
調整額 Adjustment	△ 9,246	△ 9,331	△ 84	—
売上高 Net sales	127,784	155,143	27,359	21.4%
売上原価 Cost of sales	76,361	86,872	10,511	13.8%
売上総利益 Gross profit	51,422	68,270	16,847	32.8%
運送費、保管料 Transportation and storage	5,248	5,752	504	9.6%
広告宣伝費 Advertising	992	1,122	130	13.1%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	16,885	15,626	△ 1,258	△ 7.5%
研究開発費 Research and development	2,579	2,847	267	10.4%
管理費、その他 Other, net	19,935	21,305	1,370	6.9%
販売費及び一般管理費 SG&A expenses	45,639	46,653	1,013	2.2%
宝酒造 Takara Shuzo	1,626	2,270	644	39.6%
宝酒造インターナショナルグループ Takara Shuzo International Group	△ 396	4,304	4,700	—
タカラバイオ グループ Takara Bio Group	3,736	14,105	10,368	277.5%
その他 Other	847	1,029	181	21.4%
調整額 Adjustment	△ 31	△ 93	△ 62	—
営業利益(△:損失) Operating income(△:loss)	5,782	21,616	15,833	273.8%
受取利息・配当金 Interest and Dividends income	370	381	10	2.9%
その他営業外収益 Other, net	261	287	25	9.9%
営業外収益 Non-operating income	632	669	36	5.8%
支払利息 Interest and discounts expenses	176	160	△ 15	△ 8.8%
その他営業外費用 Other, net	298	239	△ 58	△ 19.7%
営業外費用 Non-operating expenses	474	400	△ 74	△ 15.7%
経常利益(△:損失) Ordinary income(△:loss)	5,940	21,884	15,944	268.4%
特別利益 Extraordinary income	3	1,368	1,365	43,214.5%
特別損失 Extraordinary loss	617	2,853	2,236	362.3%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	5,326	20,400	15,073	283.0%
法人税、住民税及び事業税 Current income taxes	2,087	6,396	4,309	206.4%
法人税等調整額 Deferred income taxes	△ 189	△ 354	△ 165	—
四半期純利益(△:損失) Net income(△:loss)	3,428	14,358	10,930	318.8%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	666	4,308	3,641	546.4%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	2,761	10,050	7,288	263.9%
設備投資額(有形・無形) Capital expenditures	8,448	8,811	362	4.3%
減価償却費(有形・無形) Depreciation and Amortization	3,997	4,061	64	1.6%
のれん償却額 Amortization of goodwill	432	432	△ 0	△ 0.1%

②宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期	対前期	
	第2四半期累計	第2四半期累計	Change from FY2021(1Q-2Q)	
	実績(a) FY2021(1Q-2Q) Actual (a)	実績(b) FY2022(1Q-2Q) Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
焼酎 Shochu	24,284	24,173	△ 111	△ 0.5%
清酒 Sake	6,792	6,066	△ 726	△ 10.7%
ソフトアルコール飲料 Light-alcohol refreshers	24,024	23,115	△ 909	△ 3.8%
その他酒類 Other liquors	2,684	2,828	143	5.4%
本みりん Hon Mirin	6,288	6,344	56	0.9%
その他調味料 Other seasonings	4,976	5,093	117	2.4%
原料用アルコール等 Raw alcohol	5,114	3,928	△ 1,185	△ 23.2%
売上高 Net sales	74,164	71,549	△ 2,615	△ 3.5%
売上原価 Cost of sales	45,183	43,341	△ 1,841	△ 4.1%
売上総利益 Gross profit	28,981	28,207	△ 774	△ 2.7%
運送費、保管料 Transportation and storage	4,013	3,977	△ 36	△ 0.9%
広告宣伝費 Advertising	924	1,052	127	13.8%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	16,429	14,975	△ 1,454	△ 8.9%
研究開発費 Research and development	172	183	11	6.6%
管理費、その他 Other, net	5,815	5,748	△ 67	△ 1.2%
販売費及び一般管理費 SG&A expenses	27,355	25,936	△ 1,418	△ 5.2%
営業利益(△:損失) Operating income(△:loss)	1,626	2,270	644	39.6%
営業外収益 Non-operating income	145	178	32	22.2%
営業外費用 Non-operating expenses	146	127	△ 18	△ 12.8%
経常利益(△:損失) Ordinary income(△:loss)	1,625	2,321	695	42.8%
特別利益 Extraordinary gain	—	110	110	—
特別損失 Extraordinary loss	37	1,622	1,584	4,221.9%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	1,588	809	△ 778	△ 49.0%
法人税、住民税及び事業税 Current income taxes	617	459	△ 158	△ 25.7%
法人税等調整額 Deferred income taxes	△ 104	△ 202	△ 97	—
四半期純利益(△:損失) Net income(△:loss)	1,074	552	△ 521	△ 48.6%
設備投資額(有形・無形) Capital expenditures	477	500	22	4.8%
減価償却費(有形・無形) Depreciation and Amortization	1,397	1,257	△ 140	△ 10.0%

③宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期	対前期	
	第2四半期累計	第2四半期累計	Change from FY2021(1Q-2Q)	
	実績(a) FY2021(1Q-2Q) Actual (a)	実績(b) FY2022(1Q-2Q) Actual (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
海外酒類事業 Overseas Alcoholic beverages business	4,574	7,019	2,444	53.4%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	27,099	40,410	13,311	49.1%
その他 Other	35	29	△ 6	△ 16.9%
連結消去 Elimination	△ 424	△ 710	△ 286	—
売上高 Net sales	31,286	46,748	15,462	49.4%
売上原価 Cost of sales	22,140	31,747	9,606	43.4%
売上総利益 Gross profit	9,145	15,000	5,855	64.0%
運送費、保管料 Transportation and storage	1,011	1,517	505	50.0%
広告宣伝費 Advertising	33	39	6	18.1%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	223	369	146	65.6%
管理費、その他 Other, net	8,273	8,769	496	6.0%
販売費及び一般管理費 SG&A expenses	9,541	10,696	1,154	12.1%
海外酒類事業 Overseas Alcoholic beverages business	889	2,145	1,256	141.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 530	2,904	3,434	—
その他 Other	△ 531	△ 491	39	—
連結消去 Elimination	△ 224	△ 254	△ 30	—
営業利益(△:損失) Operating income(△:loss)	△ 396	4,304	4,700	—
営業外収益 Non-operating income	88	81	△ 7	△ 7.9%
営業外費用 Non-operating expenses	141	159	17	12.6%
経常利益(△:損失) Ordinary income(△:loss)	△ 449	4,226	4,676	—
特別利益 Extraordinary gain	1	2	0	45.4%
特別損失 Extraordinary loss	35	6	△ 28	△ 82.0%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	△ 482	4,222	4,705	—
法人税、住民税及び事業税 Current income taxes	△ 66	1,108	1,174	—
法人税等調整額 Deferred income taxes	4	55	50	1,235.8%
四半期純利益(△:損失) Net income(△:loss)	△ 420	3,059	3,480	—
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	△ 239	349	589	—
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	△ 181	2,709	2,891	—
設備投資額(有形・無形) Capital expenditures	1,631	462	△ 1,169	△ 71.7%
減価償却費(有形・無形) Depreciation and Amortization	696	837	140	20.2%
のれん償却額 Amortization of goodwill	186	187	0	0.4%

MEMO

8. 2022年3月期 業績予想 :Financial forecast for the year ending March 31, 2022

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2021年3月期		2022年3月期		対前期		対8/3予想	
	FY2021		FY2022_Apr. 1, 2021 - Mar. 31, 2022		Change from FY2021		Change from forecast announced Aug. 2021	
	実績(a) Actual (a)	8/3予想(b) Forecast announced Aug. 2021 (b)	11/9予想(c) Forecast announced Nov. 2021 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)	
宝酒造 Takara Shuzo	152,537	122,504	120,078	△ 32,459	△ 21.3%	△ 2,426	△ 2.0%	
宝酒造インターナショナルグループ Takara Shuzo International Group	69,589	88,430	99,394	29,804	42.8%	10,964	12.4%	
タカラバイオ グループ Takara Bio Group	46,086	54,200	59,300	13,213	28.7%	5,100	9.4%	
その他 Other	29,238	29,846	29,864	625	2.1%	18	0.1%	
調整額 Adjustment	△ 19,007	△ 19,980	△ 19,636	△ 628	—	344	—	
売上高 Net sales	278,443	275,000	289,000	10,556	3.8%	14,000	5.1%	
売上原価 Cost of sales	162,849	177,800	185,200	22,350	13.7%	7,400	4.2%	
売上総利益 Gross profit	115,594	97,200	103,800	△ 11,794	△ 10.2%	6,600	6.8%	
運送費、保管料 Transportation and storage	10,937	11,700	12,200	1,262	11.5%	500	4.3%	
広告宣伝費 Advertising	2,251	2,700	2,600	348	15.5%	△ 100	△ 3.7%	
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	34,128	3,800	3,800	△ 30,328	△ 88.9%	—	—	
研究開発費 Research and development	5,914	6,500	6,300	385	6.5%	△ 200	△ 3.1%	
管理費、その他 Other, net	40,768	43,900	45,500	4,731	11.6%	1,600	3.6%	
販売費及び一般管理費 SG&A expenses	93,999	68,600	70,400	△ 23,599	△ 25.1%	1,800	2.6%	
宝酒造 Takara Shuzo	4,879	4,500	4,200	△ 679	△ 13.9%	△ 300	△ 6.7%	
宝酒造インターナショナルグループ Takara Shuzo International Group	1,043	6,000	8,000	6,956	666.8%	2,000	33.3%	
タカラバイオ グループ Takara Bio Group	13,952	17,000	20,000	6,047	43.3%	3,000	17.6%	
その他 Other	1,803	1,887	2,022	218	12.1%	135	7.2%	
調整額 Adjustment	△ 84	△ 787	△ 822	△ 737	—	△ 34	—	
営業利益(△:損失) Operating income(△:loss)	21,595	28,600	33,400	11,804	54.7%	4,800	16.8%	
受取利息・配当金 Interest and Dividends income	707	700	800	92	13.1%	100	14.3%	
その他営業外収益 Other, net	603	400	500	△ 103	△ 17.2%	100	25.0%	
営業外収益 Non-operating income	1,311	1,100	1,300	△ 11	△ 0.9%	200	18.2%	
支払利息 Interest and discounts expenses	344	300	350	5	1.6%	50	16.7%	
その他営業外費用 Other, net	632	400	550	△ 82	△ 13.0%	150	37.5%	
営業外費用 Non-operating expenses	976	700	900	△ 76	△ 7.8%	200	28.6%	
経常利益(△:損失) Ordinary income(△:loss)	21,929	29,000	33,800	11,870	54.1%	4,800	16.6%	
特別利益 Extraordinary income	529	4,900	5,100	4,570	863.9%	200	4.1%	
特別損失 Extraordinary loss	1,875	6,700	6,800	4,924	262.6%	100	1.5%	
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	20,583	27,200	32,100	11,516	56.0%	4,900	18.0%	
法人税、住民税及び事業税 Current income taxes	6,303	8,500	9,600	3,273	51.7%	1,100	12.9%	
法人税等調整額 Deferred income taxes	23							
当期純利益(△:損失) Net income(△:loss)	14,256	18,700	22,500	8,243	57.8%	3,800	20.3%	
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	3,682	5,300	6,400	2,717	73.8%	1,100	20.8%	
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	10,574	13,400	16,100	5,525	52.3%	2,700	20.1%	
設備投資額(有形・無形) Capital expenditures	13,775	18,350	18,350	4,574	33.2%	—	—	
減価償却費(有形・無形) Depreciation and Amortization	8,068	8,500	8,500	431	5.3%	—	—	
のれん償却額 Amortization of goodwill	865	800	900	34	4.0%	100	12.5%	

② 宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期		対前期		対8/3予想	
	FY2021	FY2022_Apr. 1, 2021 - Mar. 31, 2022		Change from FY2021		Change from forecast announced Aug. 2021	
	実績(a) Actual (a)	8/3予想(b) Forecast announced Aug. 2021 (b)	11/9予想(c) Forecast announced Nov. 2021 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)
焼酎 Shochu	48,631	38,094	37,640	△ 10,991	△ 22.6%	△ 454	△ 1.2%
清酒 Sake	17,706	12,828	13,013	△ 4,693	△ 26.5%	185	1.4%
ソフトアルコール飲料 Light-alcohol refreshers	47,154	40,710	38,695	△ 8,459	△ 17.9%	△ 2,015	△ 4.9%
その他酒類 Other liquors	5,573	5,151	5,203	△ 370	△ 6.6%	52	1.0%
本みりん Hon Mirin	13,367	8,657	8,869	△ 4,498	△ 33.7%	212	2.4%
その他調味料 Other seasonings	10,441	8,571	8,644	△ 1,797	△ 17.2%	73	0.9%
原料用アルコール等 Raw alcohol	9,663	8,493	8,014	△ 1,649	△ 17.1%	△ 479	△ 5.6%
売上高 Net sales	152,537	122,504	120,078	△ 32,459	△ 21.3%	△ 2,426	△ 2.0%
売上原価 Cost of sales	92,439	92,529	90,956	△ 1,483	△ 1.6%	△ 1,573	△ 1.7%
売上総利益 Gross profit	60,098	29,975	29,122	△ 30,976	△ 51.5%	△ 853	△ 2.8%
運送費、保管料 Transportation and storage	8,173	8,364	8,243	69	0.9%	△ 121	△ 1.4%
広告宣伝費 Advertising	2,089	2,573	2,433	343	16.4%	△ 140	△ 5.4%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,981	2,412	2,366	△ 30,615	△ 92.8%	△ 46	△ 1.9%
研究開発費 Research and development	363	381	368	4	1.1%	△ 13	△ 3.4%
管理費、その他 Other, net	11,610	11,745	11,512	△ 98	△ 0.8%	△ 233	△ 2.0%
販売費及び一般管理費 SG&A expenses	55,218	25,475	24,922	△ 30,296	△ 54.9%	△ 553	△ 2.2%
営業利益(△:損失) Operating income(△:loss)	4,879	4,500	4,200	△ 679	△ 13.9%	△ 300	△ 6.7%
営業外収益 Non-operating income	239	211	240	0	0.1%	29	13.7%
営業外費用 Non-operating expenses	402	265	267	△ 135	△ 33.6%	2	0.8%
経常利益(△:損失) Ordinary income(△:loss)	4,716	4,446	4,173	△ 543	△ 11.5%	△ 273	△ 6.1%
特別利益 Extraordinary gain	0	100	115	114	55,785.7%	15	15.0%
特別損失 Extraordinary loss	188	1,711	1,721	1,532	811.8%	10	0.6%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	4,528	2,835	2,567	△ 1,961	△ 43.3%	△ 268	△ 9.5%
法人税、住民税及び事業税 Current income taxes	1,469	969	825	△ 600	△ 42.1%	△ 144	△ 14.9%
法人税等調整額 Deferred income taxes	△ 43						
当期純利益(△:損失) Net income(△:loss)	3,102	1,866	1,742	△ 1,360	△ 43.9%	△ 124	△ 6.6%

設備投資額(有形・無形) Capital expenditures	1,430	2,094	2,094	663	46.4%	—	—
減価償却費(有形・無形) Depreciation and Amortization	2,848	2,707	2,652	△ 196	△ 6.9%	△ 55	△ 2.0%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2021年3月期		2022年3月期		対前期		対8/3予想	
	FY2021	FY2022_Apr. 1, 2021 - Mar. 31, 2022			Change from FY2021		Change from forecast announced Aug. 2021	
	実績(a) Actual (a)	8/3予想(b) Forecast announced Aug. 2021 (b)	11/9予想(c) Forecast announced Nov. 2021 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)	
海外酒類事業 Overseas Alcoholic beverages business	10,100	12,259	13,580	3,479	34.4%	1,321	10.8%	
海外日本食材卸事業 Japanese food wholesale business in overseas markets	60,431	77,580	87,430	26,998	44.7%	9,850	12.7%	
その他 Other	57	51	54	△ 3	△ 5.5%	3	5.9%	
連結消去 Elimination	△ 999	△ 1,460	△ 1,670	△ 670	—	△ 210	—	
売上高 Net sales	69,589	88,430	99,394	29,804	42.8%	10,964	12.4%	
売上原価 Cost of sales	48,983	61,348	68,245	19,261	39.3%	6,897	11.2%	
売上総利益 Gross profit	20,605	27,082	31,149	10,543	51.2%	4,067	15.0%	
運送費、保管料 Transportation and storage	2,283	2,830	3,385	1,101	48.3%	555	19.6%	
広告宣伝費 Advertising	91	103	120	28	31.0%	17	16.5%	
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	553	728	796	242	43.9%	68	9.3%	
管理費、その他 Other, net	16,634	17,421	18,848	2,213	13.3%	1,427	8.2%	
販売費及び一般管理費 SG&A expenses	19,562	21,082	23,149	3,586	18.3%	2,067	9.8%	
海外酒類事業 Overseas Alcoholic beverages business	2,256	3,143	3,671	1,414	62.7%	528	16.8%	
海外日本食材卸事業 Japanese food wholesale business in overseas markets	286	4,343	5,736	5,449	1,900.8%	1,393	32.1%	
その他 Other	△ 1,042	△ 1,045	△ 1,002	40	—	43	—	
連結消去 Elimination	△ 457	△ 441	△ 405	52	—	36	—	
営業利益(△:損失) Operating income(△:loss)	1,043	6,000	8,000	6,956	666.8%	2,000	33.3%	
営業外収益 Non-operating income	180	150	228	47	26.7%	78	52.0%	
営業外費用 Non-operating expenses	318	207	291	△ 27	△ 8.6%	84	40.6%	
経常利益(△:損失) Ordinary income(△:loss)	904	5,943	7,937	7,032	777.0%	1,994	33.6%	
特別利益 Extraordinary gain	3	—	3	△ 0	△ 17.8%	3	—	
特別損失 Extraordinary loss	477	149	150	△ 327	△ 68.6%	1	0.7%	
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	431	5,794	7,790	7,358	1,705.7%	1,996	34.4%	
法人税等 Current income taxes, etc.	△ 7	1,840	2,101	2,073	7,487.5%	261	14.2%	
法人税等調整額 Deferred income taxes	35							
当期純利益(△:損失) Net income(△:loss)	403	3,954	5,689	5,285	1,309.1%	1,735	43.9%	
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	△ 84	612	820	904	—	208	34.0%	
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	487	3,342	4,869	4,381	898.2%	1,527	45.7%	
設備投資額(有形・無形) Capital expenditures	2,802	1,025	1,025	△ 1,777	△ 63.4%	—	—	
減価償却費(有形・無形) Depreciation and Amortization	1,430	1,565	1,644	213	14.9%	79	5.0%	
のれん償却額 Amortization of goodwill	379	351	383	3	1.0%	32	9.1%	

④ タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期		対前期		対8/3予想	
	FY2021	FY2022_Apr. 1, 2021 - Mar. 31, 2022		Change from FY2021		Change from forecast announced Aug. 2021	
	実績(a) Actual (a)	8/3予想(b) Forecast announced Aug. 2021 (b)	11/9予想(c) Forecast announced Nov. 2021 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) YOY% (c/b-1)
試薬 Reagents	35,189	40,594	46,375	11,186	31.8%	5,781	14.2%
機器 Instruments	1,726	1,542	1,388	△ 337	△ 19.6%	△ 153	△ 9.9%
受託 CDMO	8,901	11,346	11,388	2,486	27.9%	41	0.4%
遺伝子医療 Gene Therapy	268	716	146	△ 121	△ 45.4%	△ 569	△ 79.5%
売上高 Net sales	46,086	54,200	59,300	13,213	28.7%	5,100	9.4%
売上原価 Cost of sales	14,214	16,932	18,797	4,582	32.2%	1,864	11.0%
売上総利益 Gross profit	31,872	37,267	40,502	8,630	27.1%	3,235	8.7%
運送費、保管料 Transportation and storage	742	831	865	123	16.6%	34	4.1%
広告宣伝費 Advertising	57	62	63	6	10.5%	0	1.3%
販売促進費 Sales promotion	676	810	759	82	12.3%	△ 51	△ 6.3%
研究開発費 Research and development	5,545	6,003	5,974	429	7.7%	△ 28	△ 0.5%
管理費、その他 Other, net	10,897	12,559	12,839	1,941	17.8%	280	2.2%
販売費及び一般管理費 SG&A expenses	17,919	20,267	20,502	2,583	14.4%	235	1.2%
営業利益(△:損失) Operating income(△:loss)	13,952	17,000	20,000	6,047	43.3%	3,000	17.6%
営業外収益 Non-operating income	308	258	317	8	2.9%	58	22.6%
営業外費用 Non-operating expenses	101	158	117	15	15.8%	△ 41	△ 26.2%
経常利益(△:損失) Ordinary income(△:loss)	14,159	17,100	20,200	6,040	42.7%	3,100	18.1%
特別利益 Extraordinary income	518	4,780	4,934	4,415	851.6%	154	3.2%
特別損失 Extraordinary loss	1,125	4,849	4,999	3,873	344.2%	149	3.1%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	13,552	17,030	20,135	6,582	48.6%	3,104	18.2%
法人税、住民税及び事業税 Current income taxes	4,297	5,082	5,979	2,008	50.6%	897	17.7%
法人税等調整額 Deferred income taxes	△ 326						
当期純利益(△:損失) Net income(△:loss)	9,581	11,948	14,155	4,573	47.7%	2,206	18.5%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	34	48	55	20	61.0%	6	13.8%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	9,547	11,900	14,100	4,552	47.7%	2,200	18.5%
設備投資額(有形・無形) Capital expenditures	8,897	14,795	14,795	5,897	66.3%	—	—
減価償却費(有形・無形) Depreciation and Amortization	3,220	3,687	3,623	403	12.5%	△ 64	△ 1.7%
のれん償却額 Amortization of goodwill	486	473	496	10	2.2%	23	4.9%

9. 2022年3月期 参考資料 :Reference Data for the year ending March 31, 2022

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用):Exchange rates for the income statement of overseas subsidiaries

(円 : Yen)

	2021年3月期 FY2021		2022年3月期 FY2022 Apr. 1, 2021 - Mar. 31, 2022		
	実績(a) Actual (a)	8/3予想(b) Forecast announced Aug. 2021 (b)	11/9予想(c) Forecast announced Nov. 2021 (c)	前期差 Change(c-a)	予想差 Change(c-b)
米ドル : US dollar	106.77	104.00	109.10	2.33	5.10
ポンド : Pound	137.02	135.00	150.10	13.08	15.10
ユーロ : Euro	121.88	122.00	129.60	7.72	7.60
人民元 : Yuan	15.48	15.00	16.80	1.32	1.80
100ウォン : 100 Won	9.06	8.90	9.60	0.54	0.70
インドルピー : Rupee	1.44	1.40	1.50	0.06	0.10
スウェーデンクローナ :Sweden krona	11.63	11.80	12.80	1.17	1.00
シンガポールドル :Singapore dollar	77.43	76.20	81.20	3.77	5.00
オーストラリアドル :Australian dollar	73.69	73.90	81.80	8.11	7.90

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales
(百万円 :Millions of Yen)

	対前期 Change from FY2021	対8/3予想 Change from forecast announced Aug. 2021
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	5,948	8,013
うち宝酒造インターナショナルグループ Net sales of Takara Shuzo International Group	4,328	5,782
海外酒類事業 Overseas Alcoholic beverages business	584	877
海外日本食材卸事業 Japanese food wholesale business in overseas markets	3,779	4,980
その他 Other	—	—
連結消去 Elimination	△ 35	△ 75
うちタカラバイオグループ Net sales of Takara Bio Group	1,632	2,249
研究用試薬 Research reagents	1,554	2,149
理化学機器 Scientific instruments	17	24
受託サービス Contracted service	60	74
遺伝子医療 Gene Therapy	—	—

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2021年3月期通期 実績 FY2021 Actual			2022年3月期通期 予想 FY2022 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	152,537	—	—	120,078	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	69,589	69,287	99.5%	99,394	98,996	99.6%
タカラバイオグループ Takara Bio Group	46,086	25,611	57.2%	59,300	31,539	53.2%
その他および調整額 Other / Adjustment	10,230	—	—	10,228	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	278,443	94,898	36.3%	289,000	130,535	45.2%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2021年3月期通期 実績 FY2021 Actual		2022年3月期通期 予想 FY2022 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ,loss)	売上高 Net Sales	営業利益 Operating income(Δ,loss)
米国宝酒造 Takara Sake USA Inc.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	27,554 2,941	552 58	40,795 4,450	6,220 678
宝酒造食品 Takara Shuzo Foods Co.,Ltd.	千 元 :Thousands of Yuan 百万円 :Millions of Yen	44,014 681	1,292 20	62,645 1,052	4,105 68
トマーチン The Tomatin Distillery Co.,Ltd.	千 ポンド :Thousands of Pound 百万円 :Millions of Yen	19,677 2,696	6,422 880	24,160 3,626	8,993 1,349
エイジ・インターナショナル AGE INTERNATIONAL,INC.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	30,737 3,281	14,068 1,502	35,609 3,885	16,164 1,763
フーデックスグループ FOODEX Group	千 ユーロ :Thousands of Euro 百万円 :Millions of Yen	161,182 19,644	11,945 1,455	225,192 29,184	25,664 3,326
タザキフーズ TAZAKI FOODS LTD.	千 ポンド :Thousands of Pound 百万円 :Millions of Yen	40,987 5,616	1,539 210	51,000 7,655	2,199 330
ミューチャルトレーディング Mutual Trading Co., Inc.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	283,226 30,240	Δ 16,690 Δ 1,782	410,042 44,735	11,799 1,287
ニッポンフード Nippon Food Supplies Company Pty Ltd	千 AUS ドル :Thousands of Australian dollar 百万円 :Millions of Yen	51,524 3,796	2,336 172	51,585 4,219	3,888 318
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百万円 :Millions of Yen	6,802	266	10,000	474
タカラバイオヨーロッパS.A.S.(連結) Takara Bio Europe S.A.S. Consolidated	千 ユーロ :Thousands of Euro 百万円 :Millions of Yen	51,919 6,327	8,959 1,091	62,047 8,041	11,262 1,459
宝生物工程(大連) Takara Biotechnology (Dalian) Co.,Ltd.	千 元 :Thousands of Yuan 百万円 :Millions of Yen	343,768 5,321	159,774 2,473	270,204 4,539	72,302 1,214
宝日医生物技術(北京) Takara Biomedical Technology(Beijing) Co., Ltd.	千 元 :Thousands of Yuan 百万円 :Millions of Yen	537,673 8,323	97,101 1,503	622,849 10,463	96,862 1,627
タカラコアバイオメディカル Takara Korea Biomedical Inc.	百万ウォン :Millions of Won 百万円 :Millions of Yen	12,605 1,142	2,123 192	12,299 1,180	1,938 186
タカラバイオDSSインド DSS Takara Bio India Private Limited	千 インドルピー :Thousands of Rupee 百万円 :Millions of Yen	460,020 662	63,490 91	647,772 971	96,291 144
タカラバイオUSA Takara Bio USA, Inc.	千 US ドル :Thousands of US dollar 百万円 :Millions of Yen	102,682 10,963	5,386 575	120,482 13,144	13,003 1,418

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2021			
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition	「収益認識に関する会計基準」 の適用による影響額 Effect of applying "Accounting Standards for Revenue Recognition"
売上総利益 計 Gross profit	Δ 30,976	Δ 1,189	Δ 346	Δ 29,439
(参考)原価コストダウン Reference :Cost reduction	Δ 527	※上記構成差を含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「Δ」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結)業績予想(p.14)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.14)

	2021年3月期通期 実績 FY2021 Actual		2022年3月期通期 予想 FY2022 Forecast	
	売上高 Net Sales	営業利益 Operating income(Δ,loss)	売上高 Net Sales	営業利益 Operating income(Δ,loss)
物流事業 Transportation	13,703	563	13,844	589
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	506	416	502	416
その他 Other	15,027	823	15,517	1,016
「その他」計 Total "Other"	29,238	1,803	29,864	2,022

10. 2022年3月期 業績予想【「収益認識に関する会計基準」等適用前】

Financial forecast for the year ending March 31, 2022 based on before the application of 【Accounting Standard for Revenue Recognition】

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期	対前期	
	FY2021	FY2022 Apr. 1, 2021 - Mar. 31, 2022	Change from FY2021	
	実績(a)	11/9予想(b)	増減(b-a)	率(b/a-1)
	Actual (a)	Forecast announced Nov. 2021 (b)	Change (b-a)	YOY% (b/a-1)
宝酒造 Takara Shuzo	152,537	149,517	△ 3,019	△ 2.0%
宝酒造インターナショナルグループ Takara Shuzo International Group	69,589	99,436	29,846	42.9%
タカラバイオ グループ Takara Bio Group	46,086	59,300	13,213	28.7%
その他 Other	29,238	29,864	625	2.1%
調整額 Adjustment	△ 19,007	△ 19,636	△ 628	—
売上高 Net sales	278,443	318,481	40,037	14.4%
売上原価 Cost of sales	162,849	185,200	22,350	13.7%
売上総利益 Gross profit	115,594	133,281	17,687	15.3%
運送費、保管料 Transportation and storage	10,937	12,200	1,262	11.5%
広告宣伝費 Advertising	2,251	2,600	348	15.5%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	34,128	33,281	△ 846	△ 2.5%
研究開発費 Research and development	5,914	6,300	385	6.5%
管理費、その他 Other, net	40,768	45,500	4,731	11.6%
販売費及び一般管理費 SG&A expenses	93,999	99,881	5,882	6.3%
宝酒造 Takara Shuzo	4,879	4,200	△ 679	△ 13.9%
宝酒造インターナショナルグループ Takara Shuzo International Group	1,043	8,000	6,956	666.8%
タカラバイオ グループ Takara Bio Group	13,952	20,000	6,047	43.3%
その他 Other	1,803	2,022	218	12.1%
調整額 Adjustment	△ 84	△ 822	△ 737	—
営業利益(△:損失) Operating income(△:loss)	21,595	33,400	11,804	54.7%
受取利息・配当金 Interest and Dividends income	707	800	92	13.1%
その他営業外収益 Other, net	603	500	△ 103	△ 17.2%
営業外収益 Non-operating income	1,311	1,300	△ 11	△ 0.9%
支払利息 Interest and discounts expenses	344	350	5	1.6%
その他営業外費用 Other, net	632	550	△ 82	△ 13.0%
営業外費用 Non-operating expenses	976	900	△ 76	△ 7.8%
経常利益(△:損失) Ordinary income(△:loss)	21,929	33,800	11,870	54.1%
特別利益 Extraordinary income	529	5,100	4,570	863.9%
特別損失 Extraordinary loss	1,875	6,800	4,924	262.6%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	20,583	32,100	11,516	56.0%
法人税、住民税及び事業税 Current income taxes	6,303	9,600	3,273	51.7%
法人税等調整額 Deferred income taxes	23			
当期純利益(△:損失) Net income(△:loss)	14,256	22,500	8,243	57.8%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	3,682	6,400	2,717	73.8%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	10,574	16,100	5,525	52.3%
設備投資額(有形・無形) Capital expenditures	13,775	18,350	4,574	33.2%
減価償却費(有形・無形) Depreciation and Amortization	8,068	8,500	431	5.3%
のれん償却額 Amortization of goodwill	865	900	34	4.0%

② 宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期	対前期	
	FY2021	FY2022_Apr. 1, 2021 - Mar. 31, 2022	Change from FY2021	
	実績(a) Actual (a)	11/9予想(b) Forecast announced Nov. 2021 (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
焼酎 Shochu	48,631	47,270	△ 1,360	△ 2.8%
清酒 Sake	17,706	16,502	△ 1,204	△ 6.8%
ソフトアルコール飲料 Light-alcohol refreshers	47,154	47,649	495	1.1%
その他酒類 Other liquors	5,573	5,917	344	6.2%
本みりん Hon Mirin	13,367	13,303	△ 64	△ 0.5%
その他調味料 Other seasonings	10,441	10,843	401	3.8%
原料用アルコール等 Raw alcohol	9,663	8,031	△ 1,631	△ 16.9%
売上高 Net sales	152,537	149,517	△ 3,019	△ 2.0%
売上原価 Cost of sales	92,439	90,956	△ 1,483	△ 1.6%
売上総利益 Gross profit	60,098	58,561	△ 1,536	△ 2.6%
運送費、保管料 Transportation and storage	8,173	8,243	69	0.9%
広告宣伝費 Advertising	2,089	2,433	343	16.4%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	32,981	31,805	△ 1,176	△ 3.6%
研究開発費 Research and development	363	368	4	1.1%
管理費、その他 Other, net	11,610	11,512	△ 98	△ 0.8%
販売費及び一般管理費 SG&A expenses	55,218	54,361	△ 857	△ 1.6%
営業利益(△:損失) Operating income(△:loss)	4,879	4,200	△ 679	△ 13.9%
営業外収益 Non-operating income	239	240	0	0.1%
営業外費用 Non-operating expenses	402	267	△ 135	△ 33.6%
経常利益(△:損失) Ordinary income(△:loss)	4,716	4,173	△ 543	△ 11.5%
特別利益 Extraordinary gain	0	115	114	55,785.7%
特別損失 Extraordinary loss	188	1,721	1,532	811.8%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	4,528	2,567	△ 1,961	△ 43.3%
法人税、住民税及び事業税 Current income taxes	1,469	825	△ 600	△ 42.1%
法人税等調整額 Deferred income taxes	△ 43			
当期純利益(△:損失) Net income(△:loss)	3,102	1,742	△ 1,360	△ 43.9%
設備投資額(有形・無形) Capital expenditures	1,430	2,094	663	46.4%
減価償却費(有形・無形) Depreciation and Amortization	2,848	2,652	△ 196	△ 6.9%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2021年3月期	2022年3月期	対前期	
	FY2021	FY2022, Apr. 1, 2021 - Mar. 31, 2022	Change from FY2021	
	実績(a) Actual (a)	11/9予想(b) Forecast announced Nov. 2021 (b)	増減(b-a) Change (b-a)	率(b/a-1) YOY% (b/a-1)
海外酒類事業 Overseas Alcoholic beverages business	10,100	13,622	3,521	34.9%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	60,431	87,430	26,998	44.7%
その他 Other	57	54	△ 3	△ 5.5%
連結消去 Elimination	△ 999	△ 1,670	△ 670	—
売上高 Net sales	69,589	99,436	29,846	42.9%
売上原価 Cost of sales	48,983	68,245	19,261	39.3%
売上総利益 Gross profit	20,605	31,191	10,585	51.4%
運送費、保管料 Transportation and storage	2,283	3,385	1,101	48.3%
広告宣伝費 Advertising	91	120	28	31.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	553	838	284	51.5%
管理費、その他 Other, net	16,634	18,848	2,213	13.3%
販売費及び一般管理費 SG&A expenses	19,562	23,191	3,628	18.6%
海外酒類事業 Overseas Alcoholic beverages business	2,256	3,671	1,414	62.7%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	286	5,736	5,449	1,900.8%
その他 Other	△ 1,042	△ 1,002	40	—
連結消去 Elimination	△ 457	△ 405	52	—
営業利益(△:損失) Operating income(△:loss)	1,043	8,000	6,956	666.8%
営業外収益 Non-operating income	180	228	47	26.7%
営業外費用 Non-operating expenses	318	291	△ 27	△ 8.6%
経常利益(△:損失) Ordinary income(△:loss)	904	7,937	7,032	777.0%
特別利益 Extraordinary gain	3	3	△ 0	△ 17.8%
特別損失 Extraordinary loss	477	150	△ 327	△ 68.6%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	431	7,790	7,358	1,705.7%
法人税等 Current income taxes, etc.	△ 7	2,101	2,073	7,487.5%
法人税等調整額 Deferred income taxes	35			
当期純利益(△:損失) Net income(△:loss)	403	5,689	5,285	1,309.1%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	△ 84	820	904	—
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	487	4,869	4,381	898.2%
設備投資額(有形・無形) Capital expenditures	2,802	1,025	△ 1,777	△ 63.4%
減価償却費(有形・無形) Depreciation and Amortization	1,430	1,644	213	14.9%
のれん償却額 Amortization of goodwill	379	383	3	1.0%